Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
